Peer-reviewedCC BYThe Journal of clinical investigation
Next-generation CDK inhibitors in HR+/HER2– breast cancer
- 1Dana-Farber Cancer Institute at Boston Medical Center, Brighton, Massachusetts, USA.
- 2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Related
- CDK4/6 Inhibitors in the Treatment of Advanced ER/PR-Positive, HER2-Negative Breast Cancer: An Updated Single-Center Analysis of Real-World Data
- CDK4/6 Inhibitors and Curcumin Synergistically Suppress HER2- Breast Cancer via Lethal ROS and Inhibition of Metastasis.
- Post CDK4/6 inhibitors: Novel targeted combinations based on SERDs in HR⁺/HER2⁻ advanced breast cancer.
- Safety-guided selection of CDK4/6 inhibitors in HR+/HER2− metastatic breast cancer: toxicity profiles, dose modification, and clinical risk–benefit considerations
- CT-defined sarcopenia and outcomes in HR+/HER2− metastatic breast cancer treated with CDK4/6 inhibitors
BibTeX
@article{seriak2026nextgeneration,
title = {{Next-generation CDK inhibitors in HR+/HER2– breast cancer}},
author = {Daria Seriak and Jun Yong Kim and Geoffrey I. Shapiro and Antonio Giordano},
journal = {The Journal of clinical investigation},
year = {2026},
month = oct,
url = {https://europepmc.org/article/PMC/PMC13668613},
note = {CC BY},
}
RIS
TY - JOUR
TI - Next-generation CDK inhibitors in HR+/HER2– breast cancer
AU - Daria Seriak
AU - Jun Yong Kim
AU - Geoffrey I. Shapiro
AU - Antonio Giordano
PY - 2026
DA - 2026/10/19
JO - The Journal of clinical investigation
UR - https://europepmc.org/article/PMC/PMC13668613
SN - 0021-9738
SN - 1558-8238
ER -